Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics

21st September 2017 (Last Updated September 21st, 2017 18:30)

Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.

Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.

The Irish biopharmaceutical company plans to use the funds for general corporate purposes.

US-based drug discovery company LifeMine Therapeutics has secured $55m in a series A funding round led by WuXi Healthcare Ventures.

LifeMine plans to use the funds towards the development of innovative drugs.

Aldeyra Therapeutics has announced an underwritten public offering of three million shares of its common stock priced at $7.25 a share to raise $25m in total.

The US-based biotechnology company plans to use the funds towards the development of ADX-102 and other product candidates.

"US-based drug discovery company LifeMine Therapeutics has secured $55m in a series A funding round led by WuXi Healthcare Ventures."

Berkeley Lights has formed a partnership with Bayer to enable the latter to use its Beacon platform in drug development process.

The Beacon platform helps in accelerating cell line development and antibody discovery. It will help in enhancing Bayer’s drug discovery and development activities.

Berkeley Lights is a US-based provider of breakthrough platforms for bio-pharmaceutical processes.

Rodin Therapeutics has secured $27m in a venture financing round led by Atlas Venture.

The US-based novel therapeutics developer plans to use the funds towards the development of innovative drugs targeting neurological disorders.